Relevant bibliographies by topics / Endometrial cancer, adjuvant therapy

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Endometrial cancer, adjuvant therapy'

Author: Grafiati
Published: 9 March 2023
Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Endometrial cancer, adjuvant therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Endometrial cancer, adjuvant therapy"

1

Aoki, Yoichi, Hiroyuki Kanao, Xipeng Wang, Mayu Yunokawa, Kohei Omatsu, Atsushi Fusegi, and Nobuhiro Takeshima. "Adjuvant treatment of endometrial cancer today." Japanese Journal of Clinical Oncology 50, no. 7 (May 28, 2020): 753–65. http://dx.doi.org/10.1093/jjco/hyaa071.

Full text
Abstract:
Abstract Endometrial cancer frequently occurs in post-menopausal women, and the endometrium is a well-known site of cancer affecting women. Endometrial cancer is found with genital bleeding and often at an early stage. However, there are some risks of recurrence after hysterectomy. As a medical treatment after the diagnosis of endometrial cancer, appropriate adjuvant therapy is considered to lead to a decrease in the rate of recurrence and improvement of prognosis according to the determination of the cancer stage from the surgical and histopathological results. In this review, we describe post-operative adjuvant therapy administered for endometrial cancer and advanced disease, focusing on chemotherapy, radiation therapy and the combination of both. These treatments are divided according to the risk of recurrence as based primarily on the reported evidence.
APA, Harvard, Vancouver, ISO, and other styles
2

DeLeon, Maria C., Natraj R. Ammakkanavar, and Daniela Matei. "Adjuvant therapy for endometrial cancer." Journal of Gynecologic Oncology 25, no. 2 (2014): 136. http://dx.doi.org/10.3802/jgo.2014.25.2.136.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hogberg, Thomas. "Adjuvant Chemotherapy in Endometrial Cancer." International Journal of Gynecologic Cancer 20, Suppl 2 (September 2010): S57—S59. http://dx.doi.org/10.1111/igc.0b013e3181f749fd.

Full text
Abstract:
The indications for adjuvant therapy in endometrial cancer are briefly reviewed. The importance of systemic adjuvant therapy is emphasized. A short summary of randomized studies on adjuvant chemotherapy versus radiotherapy and on adjuvant sequential chemotherapy plus radiotherapy versus radiotherapy alone is given. On the basis of the present results from randomized trials, a combination of adjuvant radiotherapy and platinum-based chemotherapy seems to be most effective.
APA, Harvard, Vancouver, ISO, and other styles
4

Gerasimov, Aleksey V., Sergey E. Krasilnikov, Anna G. Kedrova, Tatyana A. Maksimenko, Nataliya S. Afonina, Olga E. Nechaeva, and Valentine V. Kosyi. "Morphological and ultrasound characteristics of endometrium in patients with breast cancer and the risk of secondary tumors." Journal of Clinical Practice 6, no. 4 (November 15, 2015): 39–47. http://dx.doi.org/10.17816/clinpract83249.

Full text
Abstract:
The analysis of features of endometrial hyperplasia in patients with breast cancer (BC) receiving adjuvant tamoxifen therapy in the period from 2011 to 2014 inclusive. 196 patients with breast cancer with ultrasound criteria of endometrial hyperplasia were examined. A postoperative histopathologic examination revealed that the lesions were endometrial hyperplasias and with 4,1% malignant findings. Hyperplasia, polyps and endometrial cancer were diagnosed in patients receiving tamoxifen, which allowed a comparison clinicoanamnestic, ultrasound, morphological and genetic characteristics of the endometrium to recover a high risk of developing a second cancer, as well as offer a pathogenic variant of its prevention. The article can be interesting as for obstetrician-gynecologist, watching women after breast cancer treatment, and oncologists, choosing a drug for adjuvant therapy.
APA, Harvard, Vancouver, ISO, and other styles
5

Gerasimov, A. V., S. E. Krasilnikov, A. G. Kedrova, N. S. Afonina, O. E. Nechaeva, T. A. Maksimenko, and V. V. Kosyi. "MORPHOLOGICAL AND ULTRASOUND CHARACTERISTICS OF ENDOMETRIUM IN PATIENTS WITH BREAST CANCER AND THE RISK OF SECONDARY TUMORS." Journal of Clinical Practice 6, no. 3 (September 15, 2015): 39–47. http://dx.doi.org/10.17816/clinpract6339-47.

Full text
Abstract:
The analysis of features of endometrial hyperplasia in patients with breast cancer (BC) receiving adjuvant tamoxifen therapy in the period from 2011 to 2014 inclusive. 196 patients with breast cancer with ultrasound criteria of endometrial hyperplasia were examined. A postoperative histopathologic examination revealed that the lesions were endometrial hyperplasias and with 4,1% malignant findings. Hyperplasia, polyps and endometrial cancer were diagnosed in patients receiving tamoxifen, which allowed a comparison clinicoanamnestic, ultrasound, morphological and genetic characteristics of the endometrium to recover a high risk of developing a second cancer, as well as offer a pathogenic variant of its prevention. The article can be interesting as for obstetrician-gynecologist, watching women after breast cancer treatment, and oncologists, choosing a drug for adjuvant therapy.
APA, Harvard, Vancouver, ISO, and other styles
6

Nama, Vivek, Amit Patel, Lisa Kirk, John Murdoch, and Joanne Bailey. "Role of Systematic Lymphadenectomy to Tailor Adjuvant Therapy in Early Endometrial Cancer." International Journal of Gynecologic Cancer 28, no. 1 (January 2018): 107–13. http://dx.doi.org/10.1097/igc.0000000000001148.

Full text
Abstract:
ObjectiveThe long-standing protocol at our center for apparent stage I and II endometrial cancers comprises hysterectomy and bilateral salpingo-oophorectomy without lymphadenectomy. Adjuvant treatment is based in line with Postoperative Radiation Therapy in Endometrial Carcinoma 1 protocol. Our aim was to quantify the number of patients who would avoid external beam radiation therapy (EBRT) in our institution if we adopted a protocol of lymphadenectomy to tailor adjuvant EBRT and its impact on cost and quality of life.DesignRetrospective case-cohort study.SettingGynecological oncology center.MethodsAll endometrial cancers treated from 2007 to 2012 were included. The European Organization for Research and Treatment of Cancer (EORTC) quality of life (QLQ-30) and endometrial cancer specific (EN-24) questionnaires were used to measure the quality of life. The NHS tariff for EBRT, VBT and lymphadenectomy were obtained from our Trust’s contract with the local commissioning groups.Main Outcome MeasuresQuality of life and cost.ResultsSystematic pelvic lymphadenectomy in early endometrial cancers of all grades would avoid EBRT in 23.3% of patients, and if performed for grade 2 and 3 cancers, 39.5% of patients would avoid EBRT. The global health scores were significantly lower, and pain scores were considerably higher in patients who received EBRT. Performing systematic lymphadenectomy and tailored adjuvant therapy in grade 2 and 3 endometrial cancers would save £134,691 and for all grades save £37,161 for every 100 patients treated with early endometrial cancer.ConclusionSystematic lymphadenectomy with tailored adjuvant therapy may offer better QoL with reduced cost to NHS without a reduction in overall survival.
APA, Harvard, Vancouver, ISO, and other styles
7

Kumar, Piyush, and Jai Kishan Goel. "Cancer Endometrium: An Update." Journal of South Asian Federation of Obstetrics and Gynaecology 4, no. 2 (2012): 75–84. http://dx.doi.org/10.5005/jp-journals-10006-1179.

Full text
Abstract:
ABSTRACT Endometrial cancer is the most common gynecological cancer in developed countries and second most common in developing countries. Its incidence is increasing in postmenopausal women. Factors related to chronic estrogen exposure are associated with a higher incidence. Abnormal uterine bleeding is the cardinal symptom. All women with suspected endometrial cancer require transvaginal ultrasonography and most will undergo endometrial biopsy; more sophisticated radiological examinations are required for preoperative staging. The general approach for treatment of endometrial cancer is hysterectomy, bilateral salpingo-oophorectomy, abdominopelvic washings, lymph node evaluation and maximal surgical cytoreduction for those with advanced disease. Postoperative adjuvant therapy [vaginal brachytherapy, external beam radiation therapy (RT), chemotherapy] may be recommended depending on the estimated risk of recurrence. Individual patient characteristics and surgical as well as pathologic staging are the main factors that are used for postsurgical risk stratification, which in turn, directs the selection of adjuvant treatment. How to cite this article Goel JK, Kumar P. Cancer Endometrium: An Update. J South Asian Feder Obst Gynae 2012;4(2):75-84.
APA, Harvard, Vancouver, ISO, and other styles
8

Hsiao, Sheng-Mou, and Lin-Hung Wei. "Controversies in the Adjuvant Therapy of Endometrial Cancer." ISRN Obstetrics and Gynecology 2011 (September 29, 2011): 1–4. http://dx.doi.org/10.5402/2011/724649.

Full text
Abstract:
Endometrial cancer is the most common malignancy of the female genital tract. Surgical treatment includes hysterectomy, bilateral salpingo-oophorectomy, and an appropriate staging procedure. Relapse of endometrial cancer may occur in patients with high risk factors, such as old age, grade 3 cancer, deep myometrial invasion, and papillary serous and clear cell types. In recent years, several randomized trials reported the results of adjuvant therapy for patients with high risk factors. Nonetheless, some controversies still exist. This paper presents and discusses the results of important randomized trials of adjuvant therapy for endometrial cancer with risk factors.
APA, Harvard, Vancouver, ISO, and other styles
9

Kuku, Stephanie, Matt Williams, and Mary McCormack. "Adjuvant Therapy in Stage III Endometrial Cancer." International Journal of Gynecological Cancer 23, no. 6 (July 2013): 1056–64. http://dx.doi.org/10.1097/igc.0b013e3182978328.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Luo, Leo, Weiji Shi, Zhigang Zhang, and C. Jillian Tsai. "Association of delayed adjuvant therapy and overall survival in early stage endometrial cancer." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 5590. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.5590.

Full text
Abstract:
5590 Background: The primary treatment for early stage endometrial cancer includes definitive surgical staging procedure followed by adjuvant therapy in women with high risk of recurrence. The optimal interval time between surgery and adjuvant therapy is unclear. Methods: 349,404 patients with primary uterine carcinoma diagnosed from 2004 and 2012 were extracted from National Cancer Database (NCDB). Study population was limited to patients with FIGO 2009 stage I and II endometrial cancer with endometroid, mucinous, clear cell, or serous histology. Adjuvant therapy included radiation therapy, chemotherapy, or a combination. A binary variable of interval time between surgery and adjuvant therapy (“early” vs. “delayed”) was created by using the median time as a cutoff. Analysis of relationship between the interval time and overall survival was performed. Results: Final analysis included 118,373 early stage endometrial cancer patients who had definitive surgical treatment. Median age was 61 (interquartile range 55-69). 87,189 patients (74%) had stage IA disease, 21,573 (18%) patients had stage IB disease, and 9,611 (8%) patients had stage II disease. 28,824 (24%) patients received adjuvant therapy after surgery. The median time from surgery to adjuvant therapy was 1.6 months (interquartile range 1.3-2.2 months). Of the patients that received adjuvant therapy, 48% received intra-vaginal brachytherapy alone, 31% received pelvic external beam radiation, and 7% received a combination of chemotherapy and brachytherapy. There was a significant difference in overall survival in patients who received adjuvant therapy within 1.6 months from surgery and 1.6 months after surgery (Log-rank test, p = 0.04). Patients with advanced age, African-American or Hispanic race, and uninsured status or government-sponsored insurance were associated with delayed treatments. Conclusions: In this large retrospective review of early stage endometrial cancer patients, delayed time between surgery and adjuvant therapy is associated with worse overall survival. Further analysis will be performed to determine an optimal timing between surgery and adjuvant therapy.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Endometrial cancer, adjuvant therapy"

1

VERDERIO, MARIA. "Terapia adiuvante nell'adenocarcinoma dell'endometrio ad alto rischio." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2012. http://hdl.handle.net/10281/44123.

Full text
Abstract:
Introduction Endometrial cancer is the most common gynecological cancer in developed countries and is diagnosed in 75-80% of cases at FIGO stage I with a 5 years survival rate of 80-90%. Furthermore, patients with high grade tumors, deep myometrial invasion or advanced stage disease have a poor prognosis and receive adjuvant therapy after surgery. It is not clear whether radiotherapy (RT), chemotherapy (CT) or radiochemotherapy (RT/CT) is better. Materials and Methods We reviewed all high risk endometrial cancer cases (Stage IB G3; IC G2-3; IIA G3 or IIA G2 with myometrial invasion > 50%; IIB; IIIA-B-C) with no residual tumors after surgery referred to S.Gerardo Hospital from Genuary 1988 to December 2011. We divided them into four groups based on the different adjuvant therapy used (RT, CT, RT/CT, none) and we have recorded, for each group, relapses and deaths. The aim of the study is to establish the best adjuvant therapy in term of overall survival and progression free survival. Results 357 patients were eligible for the study; 141 (39,5%) have received no adjuvant therapy, 114 (53,2%) RT; 62 (28,7%) CT; 40 (18%) RT/CT. Relapses were 29 (20%), 31 (27%), 22 (35%), 6 (15%) respectively with p=0.66. Median progression free survival was similar for observation arm and CT-RT arm, while RT alone and CT alone did significantly worse; overall survival was significantly better in the CT-RT arm. Conclusion The arm radiochemotherapy has a better progression-free survival and a better overall-survival, despite the fact that the patients with the most severe risk factors for relapse were preferably treated with the combined therapy. The poor performance of chemotherapy deserves further analysis.
APA, Harvard, Vancouver, ISO, and other styles
2

Petryk, Alicia Ailie. "Magnetic nanoparticle hyperthermia as an adjuvant cancer therapy with chemotherapy." Thesis, Dartmouth College, 2014. http://pqdtopen.proquest.com/#viewpdf?dispub=3634608.

Full text
Abstract:

Magnetic nanoparticle hyperthermia (mNPH) is an emerging cancer therapy which has shown to be most effective when applied in the adjuvant setting with chemotherapy, radiation or surgery. Although mNPH employs heat as a primary therapeutic modality, conventional heat may not be the only cytotoxic effect. As such, my studies have focused on the mechanism and use of mNPH alone and in conjunction with cisplatinum chemotherapy in murine breast cancer cells and a related in vivo model. MNPH was compared to conventional microwave tumor heating, with results suggesting that mNPH (mNP directly injected into the tumor and immediately activated) and 915 MHz microwave hyperthermia, at the same thermal dose, result in similar tumor regrowth delay kinetics. However, mNPH shows significantly less peri-tumor normal tissue damage. MNPH combined with cisplatinum also demonstrated significant improvements in regrowth delay over either modality applied as a monotherapy. Additional studies demonstrated that a relatively short tumor incubation time prior to AMF exposure (less than 10 minutes) as compared to a 4-hour incubation time, resulted in faster heating rates, but similar regrowth delays when treated to the same thermal dose. The reduction of heating rate correlated well with the observed reduction in mNP concentration in the tumor observed with 4 hour incubation. The ability to effectively deliver cytotoxic mNPs to metastatic tumors is the hope and goal of systemic mNP therapy. However, delivering relevant levels of mNP is proving to be a formidable challenge. To address this issue, I assessed the ability of cisplatinum to simultaneously treat a tumor and improve the uptake of systemically delivered mNPs. Following a cisplatinum pretreatment, systemic mNPs uptake was increased by 3.1 X, in implanted murine breast tumors. Additional in vitro studies showed the necessity of a specific mNP/ Fe architecture and spatial relation for heat-based cytotoxicity in cultured cells.

APA, Harvard, Vancouver, ISO, and other styles
3

Hill, Deirdre A. "Hormone use patterns, intrauterine device use, and endometrial cancer /." Thesis, Connect to this title online; UW restricted, 1997. http://hdl.handle.net/1773/10899.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Moe, Maung. "Biomarkers to individualise adjuvant systemic therapy in early breast cancer patients." Thesis, Cardiff University, 2013. http://orca.cf.ac.uk/50864/.

Full text
Abstract:
Background Adjuvant chemotherapy, endocrine therapy, anti-HER2 therapy and radiotherapy significantly improve recurrence free and overall survivals in early breast cancers. Indications for a particular therapy have been well defined. Examples include oestrogen receptor positivity for endocrine therapy; HER2/Neu protein overexpression for anti-HER2 therapy; young age group, lymph node positivity, nuclear grade 3 and triple negativity (ie, ER/PR/HER2 negative) etc for chemotherapy; lumpectomy, > 5 cm tumour size, > 4 lymph nodes involvement etc for radiotherapy. Compared to no chemotherapy adjuvant chemotherapy can reduce the 10 years breast cancer mortality risk by one third although the absolute benefit depends on the absolute risk before the adjuvant chemotherapy as the risk reduction is proportional. The absolute risk depends on the various clinical and histopathological risk factors such as age, nuclear grade, tumour size, lymph node involvement, oestrogen hormone and HER2 receptor expressions. Various clinical guidelines, prognostic/ predictive tools and tests have been developed to calculate the absolute breast cancer specific survival risks and chemotherapy benefits to help in making the decision of “potential benefit outweighs the potential treatment toxicities” to recommend the adjuvant chemotherapy on individual basis. This principle aims to identify patients with very good prognosis for whom the toxic chemotherapy could be safely omitted and also patients with prognosis poor enough to justify offering toxic chemotherapies. However, no studies have specifically focussed on identifying patients in whom the chemotherapy could not deliver the expected benefit. Analysing molecular biomarker proteins that are functionally important in the cancer biology and chemotherapy cell killing mechanism using readily available and relatively inexpensive immunohistochemistry (IHC) method might be able to identify this Biomarkers to individualise adjuvant systemic therapy in early breast cancer Page 5 group of patients and find the targets against which novel therapy could be developed to improve their survival outcomes.
APA, Harvard, Vancouver, ISO, and other styles
5

Wirth, Manfred, and Michael Fröhner. "A Review of Studies of Hormonal Adjuvant Therapy in Prostate Cancer." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-134738.

Full text
Abstract:
There is increasing interest in the use of adjuvant hormonal therapies, which are given after the resection or destruction of all gross disease, in early-stage prostate cancer, as a significant proportion of patients experience progression and/or die from the disease despite undergoing therapy with curative intent. Several retrospective studies suggest that adjuvant hormonal therapy may improve long-term outcome after radical surgery in men with positive lymph nodes, although this approach has yet to be studied in a prospective setting. No studies of adjuvant therapy for patients with extracapsular extension at surgery have been completed, but in an interim analysis of an open controlled trial, adjuvant flutamide significantly improved progression-free survival at 4 years. Three prospective studies in the radiotherapy setting have shown that adjuvant luteinizing hormone-releasing hormone (LH-RH) agonist therapy significantly improves progression-free and/or overall survival. Future studies need to define patient subgroups who will benefit most from adjuvant therapy. The side effects of the different therapeutic options also need to be compared. It is hoped that many of the outstanding questions concerning adjuvant hormonal therapy will be answered by the ongoing Bicalutamide Early Prostate Cancer Programme
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich
APA, Harvard, Vancouver, ISO, and other styles
6

Wirth, Manfred, and Michael Fröhner. "A Review of Studies of Hormonal Adjuvant Therapy in Prostate Cancer." Karger, 1999. https://tud.qucosa.de/id/qucosa%3A27593.

Full text
Abstract:
There is increasing interest in the use of adjuvant hormonal therapies, which are given after the resection or destruction of all gross disease, in early-stage prostate cancer, as a significant proportion of patients experience progression and/or die from the disease despite undergoing therapy with curative intent. Several retrospective studies suggest that adjuvant hormonal therapy may improve long-term outcome after radical surgery in men with positive lymph nodes, although this approach has yet to be studied in a prospective setting. No studies of adjuvant therapy for patients with extracapsular extension at surgery have been completed, but in an interim analysis of an open controlled trial, adjuvant flutamide significantly improved progression-free survival at 4 years. Three prospective studies in the radiotherapy setting have shown that adjuvant luteinizing hormone-releasing hormone (LH-RH) agonist therapy significantly improves progression-free and/or overall survival. Future studies need to define patient subgroups who will benefit most from adjuvant therapy. The side effects of the different therapeutic options also need to be compared. It is hoped that many of the outstanding questions concerning adjuvant hormonal therapy will be answered by the ongoing Bicalutamide Early Prostate Cancer Programme.
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
APA, Harvard, Vancouver, ISO, and other styles
7

Little, Sarah Ann. "Hepatic malignancy neo-adjuvant therapy and surgical management : clinical and in vivo studies /." Available from the University of Aberdeen Library and Historic Collections Digital Resources. Restricted: no access, contains 3rd party material and therfore cannot be made available electronically, 2008. http://digitool.abdn.ac.uk:80/webclient/DeliveryManager?application=DIGITOOL-3&owner=resourcediscovery&custom_att_2=simple_viewer&pid=26220.

Full text
Abstract:
Thesis (M.Phil.)--Aberdeen University, 2008.
Title from web page (Viewed on July 29, 2009). With: Improvement in perioperative outcome after hepatic resection : analysis of 1,803 consecutive cases over the past decade / W. R. Jarnagan ... et al Ann. Surg. 2002: 236(4), 397-407. With: Diabetes is associated with increased perioperative mortality but equivalent long-term outcome after hepatic resection for colorectal cancer / Sarah A. Little ... et al. J. Gastrointest. Surg. 2002: 6, 88-94. With: Tumours of the ampulla and bile ducts / S. A. Little ... et al. in: Current diagnosis and management in gastroenterology / S. L. Friedman, K. R. McQuaid, J. H. Grendell (eds). With: Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholanagiocarcinona : implications for adjuvant therapeutic strategies / S. A. Little ... et al. Cancer: 2003: 15, 98(8) 1689-700. With: Hepatocellular carcinoma : current surgical management / S. A. Little Y. Fong. Seminars in oncology 2001: 28, 5 474-486. With: Neoadjuvant treatment of hepatic malignancy : an oncolytic herpes simplex virus expressing 1L-12 effectively treats the parent tumor and protects against recurrence after resection /W.R. Jarnagin ... et al. Cancer gene therapy. 2003: 10: 215-223. With: The neo-adjuvant combination of an oncolytic HSV-1 with external beam radiation has potent additive effects against a nude mouse model of human cholangiocarcinoma / J. S. Zagwer ... et al. Wangelsteen Surgical Forum. 2001: LII, 252-255. With: Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy / W.R. Jarnagin Cancer gene therapy. 2006: 13, 3, 326-34. Includes bibliographical references.
APA, Harvard, Vancouver, ISO, and other styles
8

Lukefahr, Ashley Leigh. "THE ROLE OF TURMERIC AS AN ADJUVANT THERAPEUTIC FOR OSTEOLYTIC BREAST CANCER BONE METASTASES." Thesis, The University of Arizona, 2015. http://hdl.handle.net/10150/531833.

Full text
Abstract:
A Thesis submitted to The University of Arizona College of Medicine - Phoenix in partial fulfillment of the requirements for the Degree of Doctor of Medicine.
Zoledronic acid (ZA), the gold standard treatment for breast cancer‐derived osteolytic bone lesions, induces apoptosis in mature osteoclasts. Curcumin, a plant‐dervied component of turmeric (Curcuma longa), inhibits osteoclast differentiation. This study aimed to determine the in vitro and in vivo effects of ZA and curcuminoids, alone and combined, on osteoclast differentiation and survival, breast cancer cell growth, breast cancer cell‐induced osteolytic bone lesion area, and bone mineral density (BMD). Curcuminoids, but not ZA, inhibited osteoclast formation at doses that did not alter precursor viability, as assessed by osteoclastogenesis assays using murine RAW 264.7 cells. Combined curcuminoids and ZA did not differ from curcuminoids alone in their effects on osteoclast survival/formation. The half maximal inhibitory concentration (IC50) for ZA alone was 4 μM, while the IC50 for curcuminoids plus ZA was 6μM. Curcuminoids and ZA inhibit in vitro cell viability of human breast cancer‐ derived MDA‐MB‐231 cells, as assessed by MTT assays. The IC50 of ZA alone was projected to be 1.0677 x 10^4 μM, while the IC50 for curcuminoids alone (9.1 x 10^1 μM), was close to the IC50 for curcuminoids plus ZA (1.31 x 10^2 μM curcuminoids with 300 μM ZA). In vivo effects of ZA (2 μg/kg/d) and curcuminoids (25 mg/kg/d), alone and combined, on osteolytic bone lesions dervied from innoculation with MDA‐MB‐231 cells were assessed. Radiographically‐evident osteolytic bone lesion area did not differ between treatment groups, with a trend towards decreased osteolytic lesion area in mice treated with ZA. BMD In non‐responders, without bone or pericardiac tumors, assessed by dual energy x‐ray absorptiometry, was increased in mice administered ZA. Thus, for the first time, the combined in vitro effects of ZA and curcuminoids on osteclast formation and survival were demonstrated, as well as the combined effects of ZA and curcuminoids on bresat cancer‐derived osteolytic bone lesions and BMD.
APA, Harvard, Vancouver, ISO, and other styles
9

Cardoso, Louro André. "Effects of a positive emotion-based adjuvant psychological therapy in colorectal cancer patients." Doctoral thesis, Universitat Autònoma de Barcelona, 2015. http://hdl.handle.net/10803/316573.

Full text
Abstract:
The purpose of this study is to examine the effectiveness of a Psychological Intervention based on the positive psychology and the cognitive behavioral therapy in relieving “psychological problems” at the time of adjuvant chemotherapy treatment (Folfox Protocol) in patients with colorectal cancer. This Psychological Intervention is structured and designed to enhance positive emotions in these patients and will be called “Enhancing Positive Emotions Procedure” (EPEP). The design of this study was of two groups with pre-post-test and follow-up comparisons. All participants were recruited between October of 2012 and February of 2014. 52 subjects diagnosed with colorectal cancer were recruited at the Portuguese Institute of Oncology, Oporto, Portugal. Results of this research suggest that some features could be modified by the EPEP procedure, whereas some others would remain unchanged. Some dimensions of quality of life, as well as anxiety and positive emotions could be slightly improved by the EPEP Thus, coping skills and depression would not be affected by the EPEP. Thus, it can be stated, with caution, that EPEP should be useful to improve well-being in CRC patients receiving chemotherapy.
APA, Harvard, Vancouver, ISO, and other styles
10

Trabulsi, Nora. "Adherence to adjuvant endocrine therapy in seniors with breast cancer, predictors and challenges." Thesis, McGill University, 2013. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=117097.

Full text
Abstract:
BACKGROUND: Nearly one-third of breast cancers (BC) occur in women 65 years and older. Anti-estrogen therapy (AET) significantly reduces BC recurrence and death in these patients, as they more often have hormone receptor positive tumors. However, prior studies suggest that adherence to AET in older women is a challenge. OBJECTIVE: To characterize AET adherence in seniors with BC and identify factors influencing it. METHODS: Cancer registry data and administrative claims for all non-metastatic BC diagnosed in Quebec between 1998 and 2005 were accessed from the provincial health insurance program. Patients ≥ 65 years who started AET (Tamoxifen, Anastrozole, Exemestane or Letrozole) and had 5 years of follow up were studied. Five-year medication possession ratio (MPR) was calculated and multivariate linear regression was used to assess the association between patient, disease, and physician characteristics and MPR. RESULTS: 4,715 women were included. Mean age was 72.9. 66.77% had no other significant comorbidities and only 4.16% had 3 or more comorbidities. Stage distribution was: 6.43% in situ, 74.13%localized and 19.45% regional disease. Mean MPR was 83.5% (SD 26.8%). 1596 (34%) women had AET interruption at some point during the entire period of follow up. The cumulative probability of therapy interruption was 33.8% and the mean time to interrupt was 833.4 days. Among those who had therapy interruptions, 39.1% reinstituted AET (mean time to reinstitute was 185.6 days), of which, 48.2% re-interrupted AET again. 5-year MPR decreased with increasing age (p=0.05) and hospitalizations not related to BC (0.73% per each hospitalization, p-value=0.009). Compared to women with node positive disease, those with in situ disease had on average an MPR lower by 6.5%(p-value=0.0003). Having more active prescriptions at baseline increased the MPR by 0.6% for each medication, (p-value< 0.0001). However, adding further new medications after the start of AET affected the MPR negatively (0.3% decrease in MPR for each new medication added, p-value< 0.0001). Among psychotropes, antidepressants were the only group that did show a significant effect, resulting in a MPR decrease of 4.7% among those who were known to take antidepressants prior to the diagnosis and treatment of breast cancer (p-value= 0.003). Women on Tamoxifen, compared to those on Anastrozole, had on average a MPR that is lower by 6%, (p-value= 0.002). Compared to those who never switched their AET type, those who switched early in their treatment course, during the first year, had lower MPR by 5.3% (p-value=0.003). On the other hand, those who switched later had on average an MPR higher by 7.4% (p-value<0.0001). CONCLUSION: Most seniors with BC had high adherence to AET. Patients with more advanced age, less advanced disease and more non-BC related health service use, and women treated with antidepressants prior to their breast cancer were at higher risk of suboptimal adherence.
CONTEXTE: Près d'un tiers des cancers du sein surviennent chez les femmesde 65 ans et plus. La thérapie anti-estrogènique (TAE) réduit de manière significative le risque de récidive tumorale et de décès chez les patientes, ayant des tumeurs à récepteurs hormonaux positifs. Cependant, des etudes antérieures suggèrent que l'adhérence à la TAE chez les patientes âgées est sous-optimale. OBJECTIF: Caractériser l'adhérence à la TAE chez les personnes âgées atteintes d'un cancer du sein et identifier les facteurs qui l'influencent. MÉTHODES: Les données du registre du cancer et de reclamations administratives pour tous les cas de cancer du sein non-métastatique diagnostiqués au Québec entre 1998 et 2005 ont été accédées à partir du programme provinciald'assurance-santé. Les patientes âgés de 65 ans ou plus qui ont commencé une TAE (tamoxifène,anastrozole, exémestane oulétrozole) et ont eu 5 ans de suivi ont été étudiées. Le ratio de possession de médicaments à cinq ans (RPM) a été calculé et l'analyse par régression linéaire multivariée a été utilisée pour évaluer l'association entre les caractéristiques des patientes,de leur maladie, les caractéristiques et des médecins traitants. RÉSULTATS: 4,715 femmes ont été inclus. L'âge moyen était de 72,9. 66,77% n'avaient pas d'autres morbidités significatives et seulement 4,16% avaient 3 ou plus des comorbidités. La distribution par stade était: 6,43% in situ, 74.13% cancer localisé et 19.45% maladie régionale. Le RPM moyen était de 83,5% (SD 26,8%). 1596 (34%) des femmes ont eu une interruption de TAE durant la période de suivi. La probabilité cumulée d'interruption était de 33,8% et le temps moyen àa l'interruption était de 833,4 jours. Parmi ceux qui ont subi des interruptions de thérapie, 39,1% ont par la suite réétabli leur TAE (temps moyen de 185,6 jours). De ceux-ci, 48,2% re-interrompu leur TAE. Le RPM avait tendance à diminuer avec l'âge (p = 0,05) et les hospitalisations non-liées au cancer du sein (0,73% pour chaque hospitalisation, p = 0,009). Comparativement aux femmes atteintes d'un cancer à ganglions positifs, celles avec une maladie in situ avaient en moyenne un RPM inférieure de 6,5% (valeur p = 0,0003). Un plus grand nombre de prescriptions actives au depart augmentait le RPM de 0,6% pour chaque médicament, (p <0,0001). Toutefois, l'ajout de nouveaux médicaments après le début de la TAE affectait négativement le RPM (0,3% de baisse en MPR pour chaque nouveau medicament ajouté, p <0,0001). Parmi les psychotropes, les antidépresseurs étaient le seul groupe qui a démontré un impact significatif, entraînant unediminution de 4,7% du RPM chez celles sur antidépresseurs avant le diagnostic et le traitement du cancer du sein (p = 0,003). Les patients sur tamoxifène, comparativement à ceux de l'anastrozole, avaient en moyenne un RPM inférieur de 6%, (p 0,002). Comparé à ceux qui n'ont jamais changé leur type de AET, ceux qui ont changé en début de traitement avaient un RPM plus faible de 5,3% (p = 0,003). D'autre part, celles ayant changé de type de TAE plus tard, avaient en moyenne un RPM supérieur de 7,4% (p <0,0001). CONCLUSION: La plupart des personnes âgées atteintes de cancer du sein hormonosensibl avaient une bonne adhérence à la TAE. Les patientes avec un âge plus avancé, une tumeur précoce, l'usage accru de services de santé, et les femmes traitées avec des antidépresseurs avant leur cancer du sein étaient plus à risque de adhérence sous-optimale.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Endometrial cancer, adjuvant therapy"

1

Castiglione, Monica, and Martine J. Piccart, eds. Adjuvant Therapy for Breast Cancer. Boston, MA: Springer US, 2009. http://dx.doi.org/10.1007/978-0-387-75115-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Henderson, I. Craig, ed. Adjuvant Therapy of Breast Cancer. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3496-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Craig, Henderson I., ed. Adjuvant therapy of breast cancer. Boston: Kluwer Academic Publishers, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

International Conference on the Adjuvant Therapy of Cancer. (5th 1987 Tucson, Ariz.). Adjuvant therapy of cancer V. Orlando: Grune & Stratton, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Senn, Hans Jörg, Richard D. Gelber, Aron Goldhirsch, and Beat Thürlimann, eds. Adjuvant Therapy of Breast Cancer V. Berlin, Heidelberg: Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-642-79278-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Senn, Hans-Jörg, Richard D. Gelber, Aron Goldhirsch, and Beat Thürlimann, eds. Adjuvant Therapy of Breast Cancer IV. Berlin, Heidelberg: Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-84745-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Senn, Hans-Jörg, Aron Goldhirsch, Richard D. Gelber, and Bruno Osterwalder, eds. Adjuvant Therapy of Primary Breast Cancer. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-83337-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

-J, Senn H., and International Conference on Adjuvant Therapy of Primary Breast Cancer, (5th : 1995 : St. Gall, Switzerland), eds. Adjuvant therapy of breast cancer 5. Berlin: Springer, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hansjörg, Senn, and International Conference on "Adjuvant Therapy of Primary Breast Cancer" (4th : 1992 :, eds. Adjuvant therapy of breast cancer IV. Berlin: Springer-Verlag, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Senn, Hans-Jörg, Richard D. Gelber, Aron Goldhirsch, and Beat Thürlimann, eds. Adjuvant Therapy of Primary Breast Cancer VI. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-45769-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Endometrial cancer, adjuvant therapy"

1

Sood, Kanika Sharma. "Adjuvant Radiation Therapy in Carcinoma Endometrium: An Update." In Recent Advances in Endometrial Cancer, 179–92. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-5317-2_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Assikis, V. J., and V. C. Jordan. "Tamoxifen and Endometrial Cancer: From Experiment to Patient." In Adjuvant Therapy of Breast Cancer V, 61–71. Berlin, Heidelberg: Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-642-79278-6_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Clark, Leslie H., and Victoria L. Bae-Jump. "Metformin as Adjuvant Therapy in Ovarian and Endometrial Cancers." In Energy Balance and Cancer, 279–304. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-63483-8_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Fentiman, Ian. "Adjuvant Therapy." In Male Breast Cancer, 115–28. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-04669-3_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Vogel, Charles L. "Adjuvant Therapy." In Encyclopedia of Cancer, 1–2. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-27841-9_112-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Vogel, Charles L. "Adjuvant Therapy." In Encyclopedia of Cancer, 105–6. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-662-46875-3_112.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Vogel, Charles L. "Adjuvant Therapy." In Encyclopedia of Cancer, 79–80. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-16483-5_112.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Testa, Laura, and Renata Colombo Bonadio. "Adjuvant Therapy." In Modern Breast Cancer Imaging, 435–38. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-84546-9_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Gordon, Brittaney-Belle E., Orit Kaidar-Person, Mahesh Varia, and Ashley A. Weiner. "Endometrial Cancer." In Hypofractionated and Stereotactic Radiation Therapy, 383–98. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-92802-9_27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Veronesi, Umberto. "Adjuvant Systemic Therapy." In Breast Cancer, 50–55. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-76054-9_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Endometrial cancer, adjuvant therapy"

1

Chakraborti, Basumita, Anik Ghosh, Jaydip Bhaumik, and Asima Mukhopadhyay. "Can initial grade of endometrial cancer presenting at Tata Medical Center, predict high risk factors which will require lymph node dissection and adjuvant therapy?" In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685398.

Full text
Abstract:
Background: Pre-operative tumor grade influences the type of surgery planned for endometrial cancer, while the final grade affects the adjuvant therapy. Aims and Objectives: To predict whether pre surgery tumour grade can predict tlymph node dissection and adjuvant therapy in endometriod endometrial cancer. Methods: Retrospective observational study. Data was obtained from electronic hospital medical records system. All women with a diagnosis of endometrioid endometrial cancer who attended TMC, Kolkata between September 2011 and June 2015 included. Review of the histology was asked in all patients and MDT was planned for all patients. Most of the patients operated in TMC underwent standard pre-operative imaging work up like MRI pelvis and CT upper abdomen and chest evaluation. Staging/completion surgery included total hysterectomy, BSO, pelvic +/- para aortic lymphadenectomy +/- Omental biopsy. The surgico-pathological evaluation included histology, grade, myometrial invasion, adnexal involvement and nodal involvement. Results: 155 patients had both initial and final histology. Of total 67 patients with initial grade 1 histology, 8 (12%) were upgraded to G2 and 1 (1.5%) was upgraded to G3. 35 patients with G2 disease 2 (5.7%) were upgraded to G3. Among 8 patients with G3, 7 continued to be G3. Of the 67 patients with initial grade 1, > 50% invasion was seen in 25 (37.3%). Of 35 patients with initial G2, > 50% myometrial invasion was seen in 13 (37.1%) patients. Among 8 initial G3 patients, > 50% invasion was seen in 3 (37.5%) patients. Of these 67 patients with grade 1, pelvic lymph nodes were involved in 4 (6%) patients. None of the grade 2 tumors had pelvic lymph node involvement. One (12.5%) out of 8 patients with initial G3 tumor had pelvic lymph node involvement. Recurrence was seen in 3/67 (4.5%) of G1 patients, 7/35 (20%) with G2 cases and 1/8 (12.5%) with G3 cases. Conclusion: Patients with initial G1 disease, about 13% were upgraded. Recurrence rate increased with G2 patients. For all initial grade tumors the mymetrial involvement > 50% was 37%. For initial G1 patients the pelvic lymph node involvement was found to be 6%. For G3 tumor the pelvic lymph node involvement was 12.5%.
APA, Harvard, Vancouver, ISO, and other styles
2

Fuso, L., E. Badellino, M. Laudani, A. Carapezzi, G. Parpinel, F. Petey, M. Barboni, et al. "137 Evidence based ESMO-ESGO-ESTRO endometrial cancer guidelines: are adequate for planning adjuvant therapy?" In IGCS 2020 Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2020. http://dx.doi.org/10.1136/ijgc-2020-igcs.118.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gupta, Bindiya, Shalini Rajaram, Sandhya Jain, Neerja Goel, and Naveen Tanwar. "Collision tumor of endometrial stromal sarcoma and squamous cell cancer: A rare entity." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685363.

Full text
Abstract:
A collision tumor is defined by the presence of two separate tumors in one organ on gross, microscopic, and immunohistochemical studies and they should be distinguished from malignant mullerian mixed tumors. A 60 year old lady P8L8 presented with blood stained vaginal discharge and post menopausal bleeding. Examination revealed a 1 x 2 cm cervical growth which was reported as squamous cell carcinoma cervix. Imaging revealed myohyperplasia with normal uterine cavity. The patient underwent Type III radical hysterectomy, bilateral salphingo-oophorectomy and bilateral pelvic lymphadenectomy. The uterine corpus revealed 5 cm growth in uterine cavity which was reported as high grade endometrial stromal sarcoma and the cervical growth was non keratinising squamous cell carcinoma infiltrating the former. The lymph nodes, parametria and vaginal cuff were free of tumor. The patient was referred for adjuvant chemotherapy and radiation therapy.
APA, Harvard, Vancouver, ISO, and other styles
4

van Weelden, WJ, R. Bretveld, S. van Erp, S. Engels, A. Romano, L. Massuger, R. Lalisang, J. Pijnenborg, and M. van der Aa. "EP644 Trends over time in use of primary and adjuvant hormonal therapy for endometrial cancer: a population based study." In ESGO Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/ijgc-2019-esgo.700.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Puiggrós, Laura Cárdenas, Pedro Alberto Corzo Orantos, Isabel Núñez Márquez, Anna Taltavull Pons, Anna Taltavull Pons, Cristina Meléndez Muñoz, Anna Carbó Bagué, Hugo Javier Rosales González, Eduard Sala Hernández, and Elena Álvarez Castaño. "2022-RA-1364-ESGO Implementation of molecular classification in endometrial cancer and its impact on indication of adjuvant therapy." In ESGO 2022 Congress. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/ijgc-2022-esgo.314.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

McEachron, J., L. Marshall, V. Tran, N. Zhou, M. Kanis, C. Gorelick, and Y. Lee. "261 The impact of histology and adjuvant therapy on survival and recurrence patterns among high-grade endometrial cancer with retroperitoneal metastases." In IGCS 2020 Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2020. http://dx.doi.org/10.1136/ijgc-2020-igcs.224.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ghoniem, K., G. Dinoi, A. Larish, X. Zhou, M. AlHilli, S. Wallace, C. Wohlmuth, et al. "11 Oncologic outcomes and role of adjuvant therapy in endometrial cancer patients with low volume metastasis in the sentinel lymph nodes: an international multi-institutional study." In IGCS 2020 Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2020. http://dx.doi.org/10.1136/ijgc-2020-igcs.11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Gnant, M. "Abstract PL02: Adjuvant bisphosphonate therapy in breast cancer." In Abstracts: Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symposium - Dec 10-14, 2013; San Antonio, TX. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/0008-5472.sabcs13-pl02.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bao, Yunqi. "Review on Utilizing Grp78 on Endometrial Cancer Therapy." In 2021 International Conference on Public Art and Human Development ( ICPAHD 2021). Paris, France: Atlantis Press, 2022. http://dx.doi.org/10.2991/assehr.k.220110.115.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bolm, L., K. Ohrner, N. Gennaro, F. Rückert, BM Rau, E. Petrova, D. Bausch, et al. "Subtype specific benefit from adjuvant therapy in ampullary cancer." In Viszeralmedizin 2019. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1695457.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Endometrial cancer, adjuvant therapy"

1

Charatsi, Dimitra, Polyxeni Vanakara, Michail Nikolaou, Aikaterini Evaggelopoulou, Dimitrios Korfias, Foteini Simopoulou, Nikolaos Charalampakis, et al. Vaginal Dilator Use to Promote Sexual Wellbeing After Radiotherapy in Gynaecological Cancer Survivors: A Prospective Observational Study. Science Repository, October 2021. http://dx.doi.org/10.31487/j.ijcst.2021.03.01.sup.

Full text
Abstract:
Background: Since continuing advances in radiotherapy technology broaden the role of radiotherapy in the treatment of gynaecologic malignancies, the use of vaginal dilators has been introduced in order to mitigate the risk of vaginal stenosis. The main aims of this study were to investigate the vaginal dilator use efficacy in the treatment of radiation-induced vaginal stenosis and the vaginal dilator effect on sexual quality of life. Methods: We studied fifty-three patients with endometrial or cervical cancer. The participants were treated with radical or adjuvant external beam radiotherapy and/or brachytherapy. They were routinely examined at four time points post-radiotherapy when also they were asked to fill in a validated sexual function-vaginal changes questionnaire. A p-value less than 0.05 was considered statistically significant. Results: The vaginal stenosis grading score was decreased and the size of the vaginal dilator comfortably insertable was gradually increased throughout the year of vaginal dilator use while radiation-induced vaginal and sexual symptoms were improved throughout the year of VD use. All patients with initial grade 3 showed vaginal stenosis of grade 2 after 12 months of vaginal dilator use and 65.8% of the patients with grade 2 initial vaginal stenosis demonstrated final vaginal stenosis grade 1 while 77.8% of the participants with initial 1st size of vaginal dilators reached the 3rd vaginal dilator size after 12 months. Starting time of dilator therapy <= 3 months after the end of radiotherapy was associated with a significant decrease in vaginal stenosis. Additionally, there was an overall upward trend regarding patients’ satisfaction with their sexual life. Conclusion: Endometrial and cervical cancer survivors should be encouraged to use vaginal dilators for the treatment of vaginal stenosis and sexual rehabilitation after radiotherapy.
APA, Harvard, Vancouver, ISO, and other styles
2

Hudachek, Susan F. Predicting the Toxicity of Adjuvant Breast Cancer Drug Combination Therapy. Fort Belvoir, VA: Defense Technical Information Center, September 2012. http://dx.doi.org/10.21236/ada574076.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hudachek, Susan F. Predicting the Toxicity of Adjuvant Breast Cancer Drug Combination Therapy. Fort Belvoir, VA: Defense Technical Information Center, March 2013. http://dx.doi.org/10.21236/ada577102.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ross, Bernard A. Adjuvant Action of Hepatocyte Growth Factor in Vitamin D Therapy of Androgen-Unresponsive Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, December 2001. http://dx.doi.org/10.21236/ada401687.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Deisseroth, Albert B. Adjuvant Immunotherapy for Patients at High Risk of Recurrence Following Radiation Therapy for Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, August 2005. http://dx.doi.org/10.21236/ada466640.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Tang, Shengnan, Ran Teng, Dangsheng Zhao, Guiyuan Nie, and WenJun Zhang. The effects of Huaier granule in adjuvant therapy after curative resection of colorectal cancer: A protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2021. http://dx.doi.org/10.37766/inplasy2021.3.0041.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Zhao, YiHao, and Dongbin Zhang. Efficacy and safety of trastuzumab combined with neoadjuvant chemotherapy in Chinese patients with HER-2 positive breast cancer: a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2022. http://dx.doi.org/10.37766/inplasy2022.10.0003.

Full text
Abstract:
Review question / Objective: To systematically evaluate the efficacy and safety of docetaxel combined with carboplatin and trastuzumab (TCH) neoadjuvant chemotherapy in Chinese patients with HER2-positive breast cancer. Condition being studied: Chinese patients who have been clinically diagnosed as HER-2 positive breast cancer, not complicated with basic diseases such as heart, liver and bone marrow, and who have received established surgery after chemotherapy and cooperated with follow-up. Eligibility criteria: Non-randomized controlled trials, animal experiments, literature review, non-docetaxel combined with carboplatin and trastuzumab as adjuvant therapy in Chinese breast cancer patients, and other drugs used in the intervention group or control group.
APA, Harvard, Vancouver, ISO, and other styles
8

Zhang, Meilin, Jian Song, Hongguang Yang, Feng Jin, and Ang Zheng. Adjuvant and neoadjuvant therapy of cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2-negative, early breast cancer: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2022. http://dx.doi.org/10.37766/inplasy2022.11.0008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Endometrial cancer, adjuvant therapy' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography